One proposed rulemaking would be for ingredient, which industry stakeholders identify as N-acetyl-L-cysteine, to be allowed for use in supplements; the other is on allowing products lawfully marketed as supplements to remain available with clinical investigations conducted for those products.
NAC N-acetyl cysteine
